Risk of cancer after lumbar fusion surgery with recombinant human bone morphogenic protein-2 (rh-BMP-2).

ABSTRACT:

Study design

Retrospective cohort study among Medicare beneficiaries with lumbar spinal fusion surgery.

Objective

To determine the risk of subsequent cancer among patients who received recombinant human bone morphogenic protein (rhBMP) at surgery compared with those who did not.

Summary of background data

rhBMP is commonly used to promote bone union after spinal surgery. BMP receptors are present on multiple cancer types, but the risk of cancer after receiving rhBMP has not been well studied.

Methods

We identified 146,278 subjects aged 67 years and older who underwent surgery in 2003 to 2008 and were followed through 2010 for a new diagnosis of 1 of 26 cancers. Proportional hazards models were used to determine cancer risk associated with rhBMP use.

Results<

SUBMITTER: Cooper GS 

PROVIDER: S-EPMC4006942 | biostudies-literature | 2013 Oct

REPOSITORIES: biostudies-literature